Richard A. Gonzalez net worth and biography

Richard Gonzalez Biography and Net Worth

CEO of AbbVie

Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 48,000 people worldwide and markets medicines in more than 175 countries.

Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada.

Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.

What is Richard A. Gonzalez's net worth?: The estimated net worth of Richard A. Gonzalez is at least $89.84 million as of August 5th, 2024. Mr. Gonzalez owns 446,599 shares of AbbVie stock worth more than $89,839,641 as of March 26th. This net worth evaluation does not reflect any other investments that Mr. Gonzalez may own. Additionally, Mr. Gonzalez receives a salary of $7,190,000.00 as CEO at AbbVie. Learn More about Richard A. Gonzalez's net worth.
How old is Richard A. Gonzalez?: Mr. Gonzalez is currently 70 years old. There are 7 older executives and no younger executives at AbbVie. Learn More on Richard A. Gonzalez's age.
What is Richard A. Gonzalez's salary?: As the CEO of AbbVie Inc., Mr. Gonzalez earns $7,190,000.00 per year. Learn More on Richard A. Gonzalez's salary.
How do I contact Richard A. Gonzalez?: The corporate mailing address for Mr. Gonzalez and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Richard A. Gonzalez's contact information.
Has Richard A. Gonzalez been buying or selling shares of AbbVie?: Richard A. Gonzalez has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Richard A. Gonzalez sold 66,500 shares of the business's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a transaction totalling $12,403,580.00. Following the completion of the sale, the chairman now directly owns 446,599 shares of the company's stock, valued at $83,299,645.48. Learn More on Richard A. Gonzalez's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 6 times. They sold a total of 405,784 shares worth more than $73,278,511.54. The most recent insider tranaction occured on February, 26th when SVP Kevin K Buckbee sold 18,944 shares worth more than $3,853,399.04. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 2/26/2025.

Richard A. Gonzalez Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/5/2024	Sell	66,500	$186.52	$12,403,580.00	446,599
7/17/2024	Sell	282,845	$175.00	$49,497,875.00	513,099
2/28/2024	Sell	138,616	$177.27	$24,572,458.32	519,099
7/31/2023	Sell	18,500	$149.15	$2,759,275.00	625,294
12/9/2021	Sell	174,100	$123.23	$21,454,343.00
3/1/2021	Sell	170,113	$108.61	$18,475,972.93	450,981
11/12/2020	Sell	231,604	$96.88	$22,437,795.52
12/11/2018	Sell	16,850	$88.75	$1,495,437.50	286,203
2/28/2018	Sell	8,280	$117.88	$976,046.40	321,292
11/21/2017	Sell	218,193	$94.01	$20,512,323.93	492,030
8/7/2017	Sell	193,131	$71.00	$13,712,301.00	469,623
8/4/2017	Sell	87,899	$71.02	$6,242,586.98	342,353
8/3/2017	Sell	65,861	$71.00	$4,676,131.00	342,353
5/19/2017	Sell	71,235	$65.49	$4,665,180.15	349,462
3/8/2017	Sell	72,016	$64.25	$4,627,028.00	369,113
6/2/2016	Sell	285,953	$63.82	$18,249,520.46	624,374
5/11/2016	Sell	39,000	$63.80	$2,488,200.00	338,421
4/28/2015	Sell	102,964	$64.67	$6,658,681.88

Richard A. Gonzalez Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $201.16

$196.49

$203.12

50 Day Range

MA: $196.25

$169.19

$216.62

2 Week Range

Now: $201.16

$153.58

$218.66

Volume

6,742,701 shs

Average Volume

5,276,867 shs

Market Capitalization

$355.13 billion

P/E Ratio

83.82

Dividend Yield

3.09%

Beta

0.61

Richard Gonzalez Biography and Net Worth

What is Richard A. Gonzalez's net worth?

How old is Richard A. Gonzalez?

What is Richard A. Gonzalez's salary?

How do I contact Richard A. Gonzalez?

Has Richard A. Gonzalez been buying or selling shares of AbbVie?

Who are AbbVie's active insiders?

Are insiders buying or selling shares of AbbVie?